KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.

Marianne Sinn, Anja Lohneis, Omar Mohamed, Christoph Roderburg, Matthias Hellmann, Thomas Südhoff, Daniel C Christoph, Anett Krziwanie, Jürgen Heinz, Sabine Semrau, Anke Schlenska-Lange, Thomas J Ettrich, Ralf Ulrich Trappe, Jana Kaethe Striefler, Uwe Pelzer, Klaus-Dieter Wernecke, Hanno Riess

Oncol Res Treat 48(11) 685-695

PMID40418924
PMCIDPMC12237281
DOI10.1159/000545976
发表日期2025-05-26
入排依据:The study is an oncology randomized Phase III trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier/HR). The primary endpoint is patient-reported treatment satisfaction, and secondary endpoints include recurrent VTE and mortality, but the reported results are based on scale scores and proportions, not time-to-event analysis.
摘要

摘要

UNLABELLED: <p>Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient's preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT. METHODS: CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item ACTS Burdens scale (primary endpoint after 4 weeks) and the 3-item ACTS Benefits scale were analyzed at 4, 8 and 12 weeks. Secondary endpoints included recurrent VTE, major/clinically relevant bleeding, safety, compliance, overall mortality at 3 and 6 months, quality of life measured by the Treatment Satisfaction Questionnaire for Medication II (TSQM II) and Spitzer Index. RESULTS: Between 03/2016 and 06/2019, 247 (123 Riva/124 LMWH) patients were randomized. Mean ACTS Burdens scores after 4 weeks were 52.8 versus 51.2 in favor of rivaroxaban (p = 0.019) with mean score differences ranging from 3.3 (week 8; p = 0.001) to 2.4 (week 12; p = 0.006). The treatment effect of ACTS burden was consistent over treatment time (p < 0.001). More patients on LMWH requested to stop study treatment preterm (19.4% versus 11.1%). CONCLUSION: Oral treatment with rivaroxaban led to an improvement in patient-reported treatment satisfaction, particularly in reducing anticoagulation-related burden, resulting in less patient-requested treatment stops. </p>.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。